LEONARD JOHN M
Insider CIK 1563584 · CMRX Director · VTAE Director · Q Director · ABBV SVP, Chief Scientific Officer · NTLA President and CEO, Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics, Inc | S Sale | 2026-08-21 | 2026-08-24 | 2,785 | $13.00 | $36.2K | 1,147,064 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2026-08-21 | 2026-08-24 | 2,785 | $13.00 | $36.2K | 1,147,064 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2026-08-20 | 2026-08-24 | 19,890 | $12.60 | $250.6K | 1,149,849 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2026-08-20 | 2026-08-24 | 19,890 | $12.60 | $250.6K | 1,149,849 | SEC↗ |
| IQV IQVIA HOLDINGS INC. | A Award | 2026-04-23 | 2026-04-27 | 1,571 | — | $0 | 16,946 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2026-03-01 | 2026-03-03 | 225,400 | — | $0 | 225,400 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award | 2026-03-01 | 2026-03-03 | 156,400 | — | $0 | 1,169,739 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2026-01-05 | 2026-01-07 | 34,146 | $9.21 | $314.5K | 1,013,339 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2025-12-12 | 2025-12-12 | 8,557 | — | $0 | 0 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2025-12-12 | 2025-12-12 | 8,557 | $6.83 | $58.4K | 1,047,485 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2025-12-11 | 2025-12-12 | 49,959 | — | $0 | 8,557 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2025-12-11 | 2025-12-12 | 49,959 | $9.49 | $474.1K | 1,077,115 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2025-12-11 | 2025-12-12 | 32,832 | $9.47 | $310.9K | 1,044,283 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2025-12-11 | 2025-12-12 | 5,355 | $9.59 | $51.4K | 1,038,928 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2025-12-11 | 2025-12-12 | 49,959 | $6.83 | $341.2K | 1,127,074 | SEC↗ |
| IQV IQVIA HOLDINGS INC. | A Award | 2025-04-24 | 2025-04-25 | 1,592 | — | $0 | 15,375 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2025-03-01 | 2025-03-04 | 196,000 | — | $0 | 196,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award | 2025-03-01 | 2025-03-04 | 136,000 | — | $0 | 1,077,115 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2025-01-03 | 2025-01-07 | 26,807 | $12.18 | $326.5K | 941,115 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2025-01-01 | 2025-01-03 | 7,850 | — | $0 | 0 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2025-01-01 | 2025-01-03 | 7,850 | — | $0 | 967,922 | SEC↗ |
| IQV IQVIA HOLDINGS INC. | A Award | 2024-05-07 | 2024-05-09 | 1,047 | — | $0 | 13,783 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2024-03-01 | 2024-03-05 | 163,929 | — | $0 | 163,929 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award | 2024-03-01 | 2024-03-05 | 113,586 | — | $0 | 960,072 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2024-01-03 | 2024-01-05 | 19,223 | $29.46 | $566.3K | 846,486 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2024-01-01 | 2024-01-03 | 7,848 | — | $0 | 7,850 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2024-01-01 | 2024-01-03 | 7,848 | — | $0 | 865,709 | SEC↗ |
| IQV IQVIA HOLDINGS INC. | A Award | 2023-05-10 | 2023-05-12 | 1,063 | — | $0 | 12,736 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2023-03-01 | 2023-03-03 | 128,631 | — | $0 | 128,631 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award | 2023-03-01 | 2023-03-03 | 91,036 | — | $0 | 857,861 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2023-01-04 | 2023-01-06 | 6,673 | $37.21 | $248.3K | 766,825 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2023-01-01 | 2023-01-04 | 7,848 | — | $0 | 15,698 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2023-01-01 | 2023-01-04 | 7,848 | — | $0 | 773,498 | SEC↗ |
| IQV IQVIA HOLDINGS INC. | A Award | 2022-05-11 | 2022-05-13 | 995 | — | $0 | 11,673 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2022-03-01 | 2022-03-04 | 59,941 | — | $0 | 59,941 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award | 2022-03-01 | 2022-03-04 | 40,990 | — | $0 | 765,650 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2022-01-01 | 2022-03-04 | 7,848 | — | $0 | 23,546 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2022-01-01 | 2022-03-04 | 2,493 | $112.26 | $279.9K | 724,660 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2022-01-01 | 2022-03-04 | 7,848 | — | $0 | 727,153 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-09-01 | 2021-09-01 | 28,750 | — | $0 | 0 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-09-01 | 2021-09-01 | 15,985 | — | $0 | 11,515 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-09-01 | 2021-09-01 | 15,985 | $18.30 | $292.5K | 764,040 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-09-01 | 2021-09-01 | 28,750 | $23.46 | $674.5K | 748,055 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-09-01 | 2021-09-01 | 44,735 | $170.00 | $7.60M | 719,305 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-08-31 | 2021-09-01 | 37,833 | — | $0 | 90,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-31 | 2021-09-01 | 37,833 | $155.00 | $5.86M | 719,305 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-08-31 | 2021-09-01 | 37,833 | $14.58 | $551.6K | 757,138 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-08-30 | 2021-09-01 | 27,167 | — | $0 | 127,833 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-08-30 | 2021-09-01 | 11,637 | — | $0 | 212,501 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-08-30 | 2021-09-01 | 27,167 | $14.58 | $396.1K | 758,109 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-30 | 2021-09-01 | 216 | $160.69 | $34.7K | 719,305 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-30 | 2021-09-01 | 725 | $159.98 | $116.0K | 719,521 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-30 | 2021-09-01 | 2,598 | $159.18 | $413.5K | 720,246 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-30 | 2021-09-01 | 3,123 | $157.75 | $492.7K | 722,844 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-30 | 2021-09-01 | 4,758 | $156.96 | $746.8K | 725,967 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-30 | 2021-09-01 | 15,567 | $155.70 | $2.42M | 730,725 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-30 | 2021-09-01 | 7,428 | $154.98 | $1.15M | 746,292 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-30 | 2021-09-01 | 2,334 | $153.66 | $358.6K | 753,720 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-30 | 2021-09-01 | 2,055 | $152.81 | $314.0K | 756,054 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-08-30 | 2021-09-01 | 11,637 | $13.40 | $155.9K | 730,942 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-08-23 | 2021-08-25 | 27,139 | — | $0 | 224,138 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-23 | 2021-08-25 | 18,874 | $151.54 | $2.86M | 727,570 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-08-23 | 2021-08-25 | 27,139 | $13.40 | $363.7K | 746,444 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-23 | 2021-08-25 | 8,165 | $153.08 | $1.25M | 719,405 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-23 | 2021-08-25 | 100 | $153.52 | $15.4K | 719,305 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-08-19 | 2021-08-20 | 22,682 | — | $0 | 251,277 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-08-19 | 2021-08-20 | 22,682 | $13.40 | $303.9K | 741,987 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-19 | 2021-08-20 | 5,963 | $152.30 | $908.2K | 719,305 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-19 | 2021-08-20 | 6,993 | $151.56 | $1.06M | 725,268 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-19 | 2021-08-20 | 9,726 | $150.46 | $1.46M | 732,261 | SEC↗ |
| IQV IQVIA HOLDINGS INC. | A Award | 2021-04-15 | 2021-04-19 | 934 | — | $0 | 10,678 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-04-13 | 2021-04-15 | 10,000 | — | $0 | 10,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-04-13 | 2021-04-15 | 15,937 | — | $0 | 15,937 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-04-13 | 2021-04-15 | 10,000 | $6.83 | $68.3K | 703,368 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-04-13 | 2021-04-15 | 15,937 | $13.88 | $221.2K | 719,305 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-04-01 | 2021-04-02 | 45,000 | — | $0 | 155,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-04-01 | 2021-04-02 | 26,041 | — | $0 | 273,959 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-04-01 | 2021-04-02 | 45,000 | $14.58 | $656.1K | 705,536 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-04-01 | 2021-04-02 | 13,895 | $83.00 | $1.15M | 693,368 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-04-01 | 2021-04-02 | 26,041 | $13.40 | $348.9K | 707,263 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-04-01 | 2021-04-02 | 24,314 | $84.00 | $2.04M | 681,222 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2021-03-03 | 2021-03-05 | 188,363 | — | $0 | 188,363 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2021-03-03 | 2021-03-05 | 31,394 | — | $0 | 31,394 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-02-09 | 2021-02-09 | 56,718 | — | $0 | 68,516 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-02-09 | 2021-02-09 | 56,718 | $6.83 | $387.4K | 688,579 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-02-09 | 2021-02-09 | 28,043 | $75.00 | $2.10M | 660,536 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-02-05 | 2021-02-09 | 40,000 | — | $0 | 285,453 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-02-05 | 2021-02-09 | 881 | $68.78 | $60.6K | 631,861 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-02-05 | 2021-02-09 | 8,043 | $67.18 | $540.3K | 646,760 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-02-05 | 2021-02-09 | 40,000 | $13.40 | $536.0K | 654,803 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-02-05 | 2021-02-09 | 14,018 | $67.86 | $951.3K | 632,742 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-02-03 | 2021-02-03 | 50,000 | — | $0 | 110,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-02-03 | 2021-02-03 | 67,060 | — | $0 | 17,940 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-02-03 | 2021-02-03 | 36,858 | $73.00 | $2.69M | 614,803 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-02-03 | 2021-02-03 | 67,060 | $13.88 | $930.8K | 651,661 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-02-03 | 2021-02-03 | 30,998 | $72.00 | $2.23M | 584,601 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-02-03 | 2021-02-03 | 50,000 | $22.78 | $1.14M | 615,599 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-02-01 | 2021-02-03 | 60,000 | — | $0 | 160,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-02-01 | 2021-02-03 | 30,000 | — | $0 | 27,500 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-02-01 | 2021-02-03 | 10,000 | — | $0 | 85,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-02-01 | 2021-02-03 | 100,000 | — | $0 | 125,234 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-02-01 | 2021-02-03 | 3,497 | $64.16 | $224.4K | 528,647 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-02-01 | 2021-02-03 | 8,827 | $65.00 | $573.8K | 523,853 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-02-01 | 2021-02-03 | 26,058 | $64.13 | $1.67M | 532,680 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-02-01 | 2021-02-03 | 16,750 | $63.32 | $1.06M | 558,738 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-02-01 | 2021-02-03 | 100,000 | $6.83 | $683.0K | 575,488 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-02-01 | 2021-02-03 | 5,475 | $65.04 | $356.1K | 565,599 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-02-01 | 2021-02-03 | 16,640 | $64.10 | $1.07M | 571,074 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-02-01 | 2021-02-03 | 11,100 | $63.30 | $702.6K | 587,714 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-02-01 | 2021-02-03 | 60,000 | $22.78 | $1.37M | 598,814 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-02-01 | 2021-02-03 | 3,260 | $65.03 | $212.0K | 538,814 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-02-01 | 2021-02-03 | 9,432 | $64.09 | $604.5K | 542,074 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-02-01 | 2021-02-03 | 6,448 | $63.29 | $408.1K | 551,506 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-02-01 | 2021-02-03 | 30,000 | $18.30 | $549.0K | 557,954 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-02-01 | 2021-02-03 | 693 | $65.02 | $45.1K | 527,954 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-02-01 | 2021-02-03 | 10,000 | $13.88 | $138.8K | 533,853 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-02-01 | 2021-02-03 | 1,709 | $63.24 | $108.1K | 532,144 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-01-05 | 2021-01-05 | 6,239 | $55.86 | $348.5K | 475,488 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2020-12-31 | 2021-01-05 | 14,375 | — | $0 | 0 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2020-12-31 | 2021-01-05 | 14,375 | — | $0 | 14,375 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2020-12-31 | 2021-01-05 | 28,750 | — | $0 | 28,750 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2020-12-31 | 2021-01-05 | 14,375 | — | $0 | 481,727 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2020-11-27 | 2020-11-27 | 20,000 | — | $0 | 200,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2020-11-27 | 2020-11-27 | 15,000 | — | $0 | 57,500 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2020-11-27 | 2020-11-27 | 20,000 | $14.58 | $291.6K | 487,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2020-11-27 | 2020-11-27 | 20,000 | $39.00 | $780.0K | 467,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2020-11-27 | 2020-11-27 | 15,000 | $38.00 | $570.0K | 467,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2020-11-27 | 2020-11-27 | 15,000 | $18.30 | $274.5K | 482,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2020-11-25 | 2020-11-25 | 50,000 | — | $0 | 225,234 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2020-11-25 | 2020-11-25 | 50,000 | $6.83 | $341.5K | 517,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2020-11-25 | 2020-11-25 | 50,000 | $36.00 | $1.80M | 467,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2020-11-16 | 2020-11-18 | 20,000 | — | $0 | 220,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2020-11-16 | 2020-11-18 | 20,000 | $14.58 | $291.6K | 487,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2020-11-16 | 2020-11-18 | 20,000 | $34.00 | $680.0K | 467,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2020-11-04 | 2020-11-06 | 50,000 | — | $0 | 275,234 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2020-11-04 | 2020-11-06 | 50,000 | $26.00 | $1.30M | 467,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2020-11-04 | 2020-11-06 | 50,000 | $6.83 | $341.5K | 517,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2020-10-07 | 2020-10-09 | 5,000 | — | $0 | 325,234 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2020-10-07 | 2020-10-09 | 5,000 | $21.83 | $109.1K | 467,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2020-10-07 | 2020-10-09 | 5,000 | $6.83 | $34.1K | 472,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2020-09-01 | 2020-09-03 | 5,000 | — | $0 | 330,234 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2020-09-01 | 2020-09-03 | 5,000 | $21.83 | $109.1K | 467,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2020-09-01 | 2020-09-03 | 5,000 | $6.83 | $34.1K | 472,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2020-08-06 | 2020-08-07 | 5,000 | — | $0 | 335,234 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2020-08-06 | 2020-08-07 | 5,000 | $6.83 | $34.1K | 472,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2020-08-06 | 2020-08-07 | 5,000 | $21.83 | $109.1K | 467,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2020-07-01 | 2020-07-02 | 5,000 | — | $0 | 340,234 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2020-07-01 | 2020-07-02 | 5,000 | $6.83 | $34.1K | 472,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2020-07-01 | 2020-07-02 | 5,000 | $21.83 | $109.1K | 467,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2020-06-03 | 2020-06-05 | 5,000 | — | $0 | 345,234 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2020-06-03 | 2020-06-05 | 5,000 | $21.83 | $109.1K | 467,352 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2020-06-03 | 2020-06-05 | 5,000 | $6.83 | $34.1K | 472,352 | SEC↗ |
| IQV IQVIA HOLDINGS INC. | A Award | 2020-05-06 | 2020-05-08 | 1,492 | — | $0 | 9,744 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2020-03-02 | 2020-03-04 | 340,000 | — | $0 | 340,000 | SEC↗ |
| IQV IQVIA HOLDINGS INC. | M Exercise deriv | 2019-12-20 | 2019-12-26 | 7,000 | — | $0 | 0 | SEC↗ |
| IQV IQVIA HOLDINGS INC. | M Exercise deriv | 2019-12-20 | 2019-12-26 | 6,600 | — | $0 | 0 | SEC↗ |
| IQV IQVIA HOLDINGS INC. | M Exercise deriv | 2019-12-20 | 2019-12-26 | 6,600 | — | $0 | 0 | SEC↗ |
| IQV IQVIA HOLDINGS INC. | M Exercise | 2019-12-20 | 2019-12-26 | 6,600 | $64.93 | $428.5K | 14,852 | SEC↗ |
| IQV IQVIA HOLDINGS INC. | M Exercise | 2019-12-20 | 2019-12-26 | 6,600 | $64.86 | $428.1K | 21,452 | SEC↗ |
| IQV IQVIA HOLDINGS INC. | M Exercise | 2019-12-20 | 2019-12-26 | 7,000 | $64.52 | $451.6K | 28,452 | SEC↗ |
| IQV IQVIA HOLDINGS INC. | S Sale | 2019-12-20 | 2019-12-26 | 10,100 | $151.00 | $1.53M | 18,352 | SEC↗ |
| IQV IQVIA HOLDINGS INC. | S Sale | 2019-12-20 | 2019-12-26 | 10,100 | $155.00 | $1.57M | 8,252 | SEC↗ |
| IQV IQVIA HOLDINGS INC. | A Award | 2019-05-16 | 2019-05-20 | 1,478 | — | $0 | 8,252 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2018-12-18 | 2018-12-20 | 240,000 | — | $0 | 240,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2018-05-14 | 2018-05-15 | 8,400 | $24.00 | $201.6K | 0 | SEC↗ |
| IQV IQVIA HOLDINGS INC. | A Award | 2018-04-26 | 2018-04-30 | 2,072 | — | $0 | 6,774 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2018-01-25 | 2018-01-29 | 220,000 | — | $0 | 220,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2017-12-12 | 2017-12-14 | 72,500 | — | $0 | 72,500 | SEC↗ |
| CMRX CHIMERIX INC | A Award deriv | 2017-06-28 | 2017-06-29 | 21,000 | — | $0 | 21,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award | 2017-06-01 | 2017-06-05 | 600 | $12.09 | $7.3K | 8,400 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award | 2017-06-01 | 2017-06-05 | 7,800 | $12.06 | $94.1K | 7,800 | SEC↗ |
| Q Quintiles IMS Holdings, In | A Award | 2017-05-23 | 2017-05-25 | 2,386 | — | $0 | 4,702 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2017-01-06 | 2017-01-10 | 95,000 | — | $0 | 95,000 | SEC↗ |
| VTAE Vitae Pharmaceuticals, Inc | D To issuer deriv | 2016-10-25 | 2016-10-25 | 20,000 | $11.15 | $223.0K | 0 | SEC↗ |
| VTAE Vitae Pharmaceuticals, Inc | D To issuer deriv | 2016-10-25 | 2016-10-25 | 10,000 | $11.38 | $113.8K | 0 | SEC↗ |
| CMRX CHIMERIX INC | S Sale | 2016-09-15 | 2016-09-16 | 5,000 | $5.03 | $25.1K | 0 | SEC↗ |
| CMRX CHIMERIX INC | A Award deriv | 2016-06-24 | 2016-06-28 | 9,000 | — | $0 | 9,000 | SEC↗ |
| VTAE Vitae Pharmaceuticals, Inc | A Award deriv | 2016-05-26 | 2016-05-27 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Q Quintiles Transnational Ho | A Award deriv | 2016-05-05 | 2016-05-06 | 7,000 | — | $0 | 7,000 | SEC↗ |
| Q Quintiles Transnational Ho | A Award | 2016-05-05 | 2016-05-06 | 775 | — | $0 | 2,316 | SEC↗ |
| CMRX CHIMERIX INC | P Buy | 2015-08-21 | 2015-08-25 | 1,000 | $47.38 | $47.4K | 1,000 | SEC↗ |
| VTAE Vitae Pharmaceuticals, Inc | A Award deriv | 2015-07-29 | 2015-07-29 | 20,000 | — | $0 | 20,000 | SEC↗ |
| CMRX CHIMERIX INC | A Award deriv | 2015-06-22 | 2015-06-24 | 9,000 | — | $0 | 9,000 | SEC↗ |
| Q Quintiles Transnational Ho | A Award deriv | 2015-05-07 | 2015-05-08 | 6,600 | — | $0 | 6,600 | SEC↗ |
| Q Quintiles Transnational Ho | A Award | 2015-05-07 | 2015-05-08 | 771 | — | $0 | 1,541 | SEC↗ |
| Q Quintiles Transnational Ho | A Award deriv | 2015-03-04 | 2015-03-06 | 6,600 | — | $0 | 6,600 | SEC↗ |
| Q Quintiles Transnational Ho | A Award | 2015-03-04 | 2015-03-06 | 770 | — | $0 | 770 | SEC↗ |
| CMRX CHIMERIX INC | P Buy | 2014-11-05 | 2014-11-06 | 4,000 | $29.00 | $116.0K | 4,000 | SEC↗ |
| CMRX CHIMERIX INC | A Award deriv | 2014-06-20 | 2014-06-24 | 18,000 | — | $0 | 18,000 | SEC↗ |
| CMRX CHIMERIX INC | A Award deriv | 2014-06-20 | 2014-06-24 | 9,000 | — | $0 | 9,000 | SEC↗ |
| ABBV AbbVie Inc. | M Exercise deriv | 2013-03-15 | 2013-03-19 | 46,700 | — | $0 | 46,700 | SEC↗ |
| ABBV AbbVie Inc. | S Sale | 2013-03-15 | 2013-03-19 | 46,700 | $38.45 | $1.80M | 107,320 | SEC↗ |
| ABBV AbbVie Inc. | M Exercise | 2013-03-15 | 2013-03-19 | 46,700 | $28.86 | $1.35M | 154,020 | SEC↗ |
| ABBV AbbVie Inc. | S Sale | 2013-03-08 | 2013-03-12 | 23,644 | $37.50 | $886.6K | 107,320 | SEC↗ |
| ABBV AbbVie Inc. | S Sale | 2013-03-08 | 2013-03-12 | 4,305 | $37.58 | $161.8K | 130,964 | SEC↗ |
| ABBV AbbVie Inc. | F Tax w/h | 2013-02-28 | 2013-03-04 | 9,407 | $36.73 | $345.5K | 135,269 | SEC↗ |
| ABBV AbbVie Inc. | M Exercise deriv | 2013-02-19 | 2013-02-21 | 29,650 | — | $0 | 29,650 | SEC↗ |
| ABBV AbbVie Inc. | F Tax w/h | 2013-02-19 | 2013-02-19 | 7,982 | $37.58 | $300.0K | 144,676 | SEC↗ |
| ABBV AbbVie Inc. | F Tax w/h | 2013-02-19 | 2013-02-21 | 25,345 | $37.58 | $952.5K | 148,981 | SEC↗ |
| ABBV AbbVie Inc. | M Exercise | 2013-02-19 | 2013-02-21 | 29,650 | $27.29 | $809.1K | 174,326 | SEC↗ |
| ABBV AbbVie Inc. | A Award deriv | 2013-02-14 | 2013-02-19 | 62,020 | — | $0 | 62,020 | SEC↗ |
| ABBV AbbVie Inc. | A Award | 2013-02-14 | 2013-02-19 | 30,360 | — | $0 | 152,658 | SEC↗ |